Dr. Reddy’s Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
- June 10, 2026
- Posted by: Kunal Singla
- Category: News
Dr. Reddy’s CMP: Rs 1,285 (2026). 52W High: Rs 1,380. 52W Low: Rs 1,148. Mkt Cap: Rs 107,217 Cr. P/E: 33.3. Analyst Consensus Target: Rs 1,275.
The Dr. Reddy’s stock prediction for 2026 from leading brokerages and research analysts covers a wide range that reflects the company’s sector dynamics, earnings trajectory and macro environment. The Dr. Reddy’s stock prediction published in this article is sourced from publicly available research and may or may not be achieved. Investors should treat any Dr. Reddy’s share price prediction as one data point and not as a guarantee of future performance.
Interest in the Dr. Reddy’s stock forecast for 2026 has grown as investors look for anchor points in a volatile market. This article reviews every dimension of the Dr. Reddy’s stock prediction that analysts are tracking, including key business drivers, bull and bear scenarios and the primary risks that could shift the Dr. Reddy’s share price prediction in either direction. The analyst consensus for 2026 should be verified with the latest brokerage reports before any investment decision.
Click Here – Get Free Investment Predictions
What Analysts Predict for Dr. Reddy’s Stock in 2026
Analyst consensus on the Dr. Reddy’s stock prediction for 2026 is tracked by leading brokerages and research firms. The table below shows the latest available Dr. Reddy’s stock forecast data from UBS and Emkay Global. All Dr. Reddy’s share price prediction figures are sourced from publicly available research and should be verified against the most current brokerage reports before publishing.
| Brokerage | Rating | Dr. Reddy’s Stock Prediction (Rs) | Updated |
|---|---|---|---|
| UBS | Sell | Rs 1,200 | 2026 |
| Emkay Global | Neutral | Rs 1,350 | 2026 |
| Analyst Consensus | — | Rs 1,275 | 2026 |
The Dr. Reddy’s stock prediction range from the analyst community reflects a genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. Each Dr. Reddy’s share price prediction from an individual brokerage should be read alongside the stated assumptions. The implied upside in the Dr. Reddy’s stock forecast from the current market price of Rs 1,285 may or may not be realised by the end of 2026.
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has now shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Dr. Reddy’s Company Overview
Dr. Reddy’s Laboratories is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Dr. Reddy’s stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk. Understanding this context is the starting point for any Dr. Reddy’s stock prediction and helps investors assess whether the analyst Dr. Reddy’s stock forecast is grounded in a realistic view of the company’s competitive position.
| Metric | Value |
|---|---|
| NSE Ticker | DRREDDY |
| Sector | Pharmaceuticals and Healthcare |
| CMP | Rs 1,285 (2026) |
| 52 Week High | Rs 1,380 |
| 52 Week Low | Rs 1,148 |
| Market Cap | Rs 107,217 Cr |
| P/E Ratio | 33.3 |
| Dr. Reddy’s Stock Prediction Consensus (12M) | Rs 1,275 |
Dr. Reddy’s Stock Prediction by Time Horizon
Analysts split the Dr. Reddy’s share price prediction across different time frames because the variables that drive the short-term view are very different from those that shape a 3 to 5 year outlook. The following three horizons give a structured way to think about the range of analyst estimates for 2026 and beyond.
Short-Term Dr. Reddy’s Stock Prediction (1 to 3 Months)
The near-term analyst view on Dr. Reddy’s Laboratories reflects current market sentiment, sector news flow and upcoming earnings data points. Analysts forming a short-term Dr. Reddy’s stock forecast are watching key support and resistance levels around the current market price of Rs 1,285. A Dr. Reddy’s share price prediction in the near term is the most uncertain of all time horizons and may or may not hold as new information emerges.
12-Month Dr. Reddy’s Stock Prediction
The 12 month Dr. Reddy’s stock prediction from leading brokerages represents the most widely cited analyst consensus for the full-year 2026 outlook. UBS has set a target of Rs 1,200 (Sell) while Emkay Global has set a target of Rs 1,350 (Neutral). Most research desks refresh their Dr. Reddy’s stock forecast within two to four weeks of each quarterly earnings print. The Dr. Reddy’s share price prediction should be verified against the most recent analyst reports before being used as an investment reference.
Long-Term Dr. Reddy’s Stock Prediction
The long-term Dr. Reddy’s stock prediction, built on a 3 to 5 year view, is based on assumptions about demand recovery, margin expansion and revenue diversification. Analysts who set a higher long-term Dr. Reddy’s stock forecast cite the company’s structural growth drivers in the Pharmaceuticals and Healthcare sector. The long-term Dr. Reddy’s share price prediction should be treated as a directional indicator and may or may not prove accurate over the forecast period.
Dr. Reddy’s Stock Forecast: Key Factors Behind the Prediction
Understanding what drives the Dr. Reddy’s stock forecast requires reviewing the variables that most analysts reference when forming their Dr. Reddy’s share price prediction for 2026. The following four factors appear consistently in research reports on the Dr. Reddy’s stock prediction and are the primary inputs into the bull and bear case scenarios.
US Generic Revenue
US generics revenue is the most watched metric in the Dr. Reddy’s stock forecast. USFDA approval timelines and price erosion rates directly affect the Dr. Reddy’s share price prediction from most research desks.
Domestic Formulations Growth
Domestic formulation growth provides a stable base that supports the Dr. Reddy’s stock prediction even when export growth faces headwinds.
R&D Pipeline
The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Dr. Reddy’s share price prediction. New product approvals are cited as catalysts for the Dr. Reddy’s stock prediction.
EBITDA Margin
Sustained EBITDA margin expansion is typically the basis for the bullish Dr. Reddy’s stock forecast. Margin recovery strengthens the Dr. Reddy’s share price prediction from most research desks.
Dr. Reddy’s Stock Prediction: Bull and Bear Scenarios
Any complete Dr. Reddy’s share price prediction must account for both positive and negative outcomes. The following scenarios are built from analyst commentary and sector data, representing the range of the Dr. Reddy’s stock prediction rather than a fresh estimate from Univest.
| Scenario | Dr. Reddy’s Stock Prediction | Key Conditions |
|---|---|---|
| Bull Case | Rs 1,200 | Strong business execution, margin improvement, favourable macro environment and sector re-rating |
| Base Case | Rs 1,275 | Steady performance, gradual recovery, margins hold, growth on track |
| Bear Case | Rs 1,200 | Demand deterioration, margin pressure, sector de-rating and macro headwinds |
The bull case Dr. Reddy’s stock forecast assumes most positive variables converge simultaneously. The bear case Dr. Reddy’s share price prediction reflects a scenario where demand deteriorates and the sector de-rates below current multiples. The base case Dr. Reddy’s stock prediction represents the analyst consensus view of Rs 1,275, which may or may not prove accurate.
How Analysts Are Reading the Dr. Reddy’s Stock Story
Analyst reviews of the Dr. Reddy’s share price prediction consistently highlight two opposing forces in 2026. The positive case for the Dr. Reddy’s stock forecast rests on the company’s core business strengths in the Pharmaceuticals and Healthcare sector, including competitive position and potential for margin or volume improvement over the next four quarters.
The cautious side of the analyst view points to near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Analysts who maintain a conservative Dr. Reddy’s stock prediction cite these as the primary reasons for staying neutral or cautious on the stock. Many research desks have revised their view since the start of 2026 as macro data evolved.
Overall, the Dr. Reddy’s stock prediction consensus from the analyst community is built on real business strengths set against real risks. Investors should read the full Dr. Reddy’s stock forecast report from each brokerage, including assumptions and risk disclosures, before using any Dr. Reddy’s share price prediction as an investment reference.
Key Risks That Could Change the Dr. Reddy’s Stock Prediction
Any Dr. Reddy’s share price prediction carries risks that could shift the Dr. Reddy’s stock forecast materially in either direction. Investors should review these risks before acting on any Dr. Reddy’s stock prediction from an analyst or research desk.
USFDA Regulatory Risk
Import alerts and warning letters from the USFDA are the most significant risks to the Dr. Reddy’s stock prediction. A facility closure would force an immediate sharp revision to the Dr. Reddy’s share price prediction.
Price Erosion in the US
Pricing pressure in US generics compresses the revenue per product and affects the Dr. Reddy’s stock forecast. Aggressive price erosion pushes the Dr. Reddy’s share price prediction toward the bear case.
R&D Execution Risk
Delays in clinical trials or approval failures affect the Dr. Reddy’s stock prediction. The Dr. Reddy’s share price prediction is particularly sensitive to key pipeline asset announcements.
Currency Risk
A strengthening rupee against the dollar reduces export realisation and affects the Dr. Reddy’s stock forecast. Currency risk is embedded in conservative Dr. Reddy’s share price prediction models.
How to Monitor the Dr. Reddy’s Stock Forecast and Make Decisions
Start by opening a demat account with a SEBI registered broker if you do not already have one. Before acting on any Dr. Reddy’s share price prediction, ensure you understand the risks involved in equity investing.
Track the Dr. Reddy’s stock prediction consensus quarterly: after every earnings release, most brokerages revise their Dr. Reddy’s stock forecast within two weeks. Comparing the revised Dr. Reddy’s stock prediction to the previous estimate tells you whether analyst sentiment on the stock is improving or deteriorating.
Compare the current market price of Rs 1,285 with the analyst target range of Rs 1,200 to Rs 1,350. The Dr. Reddy’s share price prediction band can be wide, so position size should reflect that uncertainty.
Review the Dr. Reddy’s stock prediction every quarter against the key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many.
Download the Univest iOS App or Univest Android App to track the live Dr. Reddy’s stock prediction and Dr. Reddy’s share price prediction changes in real time.
Conclusion
The Dr. Reddy’s stock prediction for 2026 reflects the analyst community’s assessment of Dr. Reddy’s Laboratories’s competitive position, earnings trajectory and macro environment. UBS sets a Sell target of Rs 1,200 while Emkay Global has a Neutral target of Rs 1,350, giving an analyst consensus of Rs 1,275. The Dr. Reddy’s stock forecast is set against near-term risks that make the Dr. Reddy’s share price prediction range wide. Any estimate should be verified with the latest brokerage reports and does not constitute investment advice from Univest.
The analyst forecast will be revised after every quarterly result. Track the latest Dr. Reddy’s stock prediction and Dr. Reddy’s share price prediction changes on the Univest Screener and app to stay updated as 2026 progresses.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Disclaimer: Data and figures in this article are sourced from publicly available information on Google and other public platforms. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Dr. Reddy’s Stock Prediction 2026
What is the Dr. Reddy’s stock prediction for 2026?
Ans. The Dr. Reddy’s stock prediction for 2026 is based on analyst consensus from leading brokerages including UBS and Emkay Global. The Dr. Reddy’s share price prediction range reflects the company’s fundamentals, sector outlook and macro environment. All estimates are analyst views and may or may not be achieved.
Is the Dr. Reddy’s stock prediction bullish or bearish?
Ans. The Dr. Reddy’s stock prediction for 2026 is divided, with UBS maintaining a Sell stance with a target of Rs 1,200. The Dr. Reddy’s stock forecast consensus points to potential movement from current levels, though the Dr. Reddy’s share price prediction range is wide, reflecting macro uncertainty.
What is the Dr. Reddy’s share price prediction based on fundamentals?
Ans. The Dr. Reddy’s share price prediction built on fundamentals considers the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking the Dr. Reddy’s stock forecast closely cite these variables as the primary drivers of the 2026 outlook. Each analyst estimate may or may not reflect actual future performance.
What is the long-term Dr. Reddy’s stock prediction?
Ans. The long-term Dr. Reddy’s stock prediction is built around the assumption that the company’s core business drivers sustain over a multi-year horizon. Analysts with a higher Dr. Reddy’s stock forecast point to demand recovery, margin improvement and revenue diversification. The long-term estimate carries more uncertainty than the 12-month consensus of Rs 1,275.
What are the key risks to the Dr. Reddy’s stock prediction?
Ans. The key risks to the Dr. Reddy’s stock prediction in 2026 include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Analysts who set a lower Dr. Reddy’s share price prediction cite these as the primary downside risks. Every estimate should be read alongside its stated risk assumptions.
What does the Dr. Reddy’s stock forecast say for 2026?
Ans. The Dr. Reddy’s stock forecast for 2026 reflects a cautiously positive analyst consensus based on the company’s fundamental strengths. UBS has a Sell rating with a target of Rs 1,200 while Emkay Global has a Neutral rating with a target of Rs 1,350. These Dr. Reddy’s share price prediction estimates may or may not prove accurate.
Where can I track the latest Dr. Reddy’s stock prediction?
Ans. You can track the latest Dr. Reddy’s stock prediction, live price and fundamentals on the official NSE and BSE websites and on the Univest app and screener, alongside every updated Dr. Reddy’s share price prediction and stock forecast from the analyst community.
